- Home
- BBAR vs RYTM Comparison
BBAR vs RYTM Comparison
Compare BBAR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAR
- RYTM
- Stock Information
- Founded
- BBAR 1886
- RYTM 2008
- Country
- BBAR Argentina
- RYTM United States
- Employees
- BBAR N/A
- RYTM N/A
- Industry
- BBAR Commercial Banks
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- BBAR Finance
- RYTM Health Care
- Exchange
- BBAR Nasdaq
- RYTM Nasdaq
- Market Cap
- BBAR 3.6B
- RYTM 3.8B
- IPO Year
- BBAR N/A
- RYTM 2017
- Fundamental
- Price
- BBAR $20.27
- RYTM $61.74
- Analyst Decision
- BBAR Buy
- RYTM Strong Buy
- Analyst Count
- BBAR 1
- RYTM 12
- Target Price
- BBAR $27.00
- RYTM $74.92
- AVG Volume (30 Days)
- BBAR 757.9K
- RYTM 940.6K
- Earning Date
- BBAR 05-21-2025
- RYTM 05-06-2025
- Dividend Yield
- BBAR 7.19%
- RYTM N/A
- EPS Growth
- BBAR N/A
- RYTM N/A
- EPS
- BBAR 0.56
- RYTM N/A
- Revenue
- BBAR $3,440,514,989.00
- RYTM $130,126,000.00
- Revenue This Year
- BBAR N/A
- RYTM $43.84
- Revenue Next Year
- BBAR N/A
- RYTM $65.62
- P/E Ratio
- BBAR $12.03
- RYTM N/A
- Revenue Growth
- BBAR N/A
- RYTM 68.06
- 52 Week Low
- BBAR $7.05
- RYTM $35.17
- 52 Week High
- BBAR $25.01
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- BBAR 59.22
- RYTM 61.94
- Support Level
- BBAR $19.40
- RYTM $59.54
- Resistance Level
- BBAR $21.07
- RYTM $62.83
- Average True Range (ATR)
- BBAR 1.40
- RYTM 4.27
- MACD
- BBAR 0.45
- RYTM 1.00
- Stochastic Oscillator
- BBAR 88.15
- RYTM 92.04
About BBAR Banco BBVA Argentina S.A. ADS
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.